Joint Formulary & PAD

Pregabalin - Restless Leg Syndrome

You are here : Home > Formulary Search > Pregabalin - Restless Leg Syndrome

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Off Label
SPC
Restrictions / Comments :
Important
Preferred
Patients with severe sleep disturbance, RLS-related / co-morbid pain or history of impulse control disorder

Documentation

Evidence Review
Restless leg syndrome - APC Paper - November 2018
Safety Information
Pregabalin Safety Messages - GP Version - SABP Aug 2020 (updated Mar 2021)
Information
Pregabalin and Gabapentin - Advice for prescribers on risk of misuse - December 2014

PAD Profile

ChemicalSubstance :
Pregabalin
Indication :
Restless Leg Syndrome
Group Name :
Keywords :
Brand Names Include :
Lyrica
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Committee Recommendations (1)

07 Nov 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Pregabalin is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.

Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome  

Please note; this is an off-label indication of a licensed medicine.

Other Indications

Below are listed other indications that Pregabalin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Restless Leg Syndrome.